Playback speed
10 seconds
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
93 views
September 20, 2024
Login to view comments.
Click here to Login